cilostazol has been researched along with Liver Dysfunction in 2 studies
Excerpt | Relevance | Reference |
---|---|---|
"The pharmacokinetic profiles of cilostazol and its metabolites following a single oral dose of cilostazol 100 mg were compared between individuals with impaired and normal liver function." | 2.69 | Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. ( Bramer, SL; Forbes, WP, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nomura, K | 1 |
Miyashita, T | 1 |
Yamamoto, Y | 1 |
Munesue, S | 1 |
Harashima, A | 1 |
Takayama, H | 1 |
Fushida, S | 1 |
Ohta, T | 1 |
Bramer, SL | 1 |
Forbes, WP | 1 |
1 trial available for cilostazol and Liver Dysfunction
Article | Year |
---|---|
Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
Topics: Administration, Oral; Adult; Area Under Curve; Cilostazol; Half-Life; Humans; Liver Diseases; Male; | 1999 |
1 other study available for cilostazol and Liver Dysfunction
Article | Year |
---|---|
Citrullinated Histone H3: Early Biomarker of Neutrophil Extracellular Traps in Septic Liver Damage.
Topics: Animals; Biomarkers; Cilostazol; Citrullination; Extracellular Traps; Histones; Lipopolysaccharides; | 2019 |